Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 Jun;37(2):117-23.
doi: 10.1007/s13318-011-0070-9. Epub 2011 Oct 21.

Formulation and evaluation of micro hydrogel of Moxifloxacin hydrochloride

Affiliations
Comparative Study

Formulation and evaluation of micro hydrogel of Moxifloxacin hydrochloride

Basavaraj K Nanjwade et al. Eur J Drug Metab Pharmacokinet. 2012 Jun.

Abstract

The field of ocular drug delivery is one of the interesting and challenging endeavors facing the pharmaceutical scientist. Novel approaches for ophthalmic drug delivery need to be established to increase the ocular bioavailability by overcoming the inherent drawbacks of conventional dosage forms. In situ hydrogels are instilled as drops into the eye and undergoes a sol-to-gel transition in the cul-de-sac, improved ocular bioavailability by increasing the duration of contact with corneal tissue, thereby reducing the frequency of administration. The purpose of the present work was to develop an ophthalmic drug delivery system using three different gelling agents with different mechanisms for in situ gelation of Moxifloxacin hydrochloride, a fluoroquinolone antibiotic. polyox (a pH-sensitive gelling agent), sodium alginate (an ion-sensitive gelling agent), and poloxamer (a temperature-sensitive gelling agent) were employed for the formation of in situ hydrogel along with HPMC K4M as viscofying agent, which increases the residence time of the drug in the ocular cavity. The promising formulations MF(4), MF(5), and MF(9) were evaluated for pH, drug content, in vitro gelation, in vitro drug release, in vivo drug release, ocular irritation, and stability. Percent drug content of 98.2, 98.76, and 99.43%; viscosity of 15.724 × 100, 16.108 × 100, and 15.213 × 100 cP at 20 rpm, cumulative percent release of 75.364, 74.081, and 71.752%, and C (max) of 1,164.16, 1,187.09, and 1,220.58 ng/ml was observed for formulation MF(4), MF(5), and MF(9), respectively. The developed formulations were therapeutically efficacious, stable, and non-irritant and provided sustained release of the drug over 8 h.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Vet J. 2006 Jul;172(1):10-28 - PubMed
    1. J Control Release. 2001 Jun 15;73(2-3):205-11 - PubMed
    1. Adv Drug Deliv Rev. 2002 Jan 17;54(1):37-51 - PubMed
    1. Surv Ophthalmol. 2004 Mar;49 Suppl 2:S73-8 - PubMed
    1. Drug Dev Ind Pharm. 2008 Jul;34(7):744-52 - PubMed

Publication types

MeSH terms

LinkOut - more resources